Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.